OHDSI Home | Forums | Wiki | Github

DAY 3 LATE UPDATE: #OHDSICOVID19 Study-A-Thon

Day 3 Updates

Early Call: Video
Global Call: Video
Wrap-Up Call: Video

LATE UPDATE

• One night removed from being an empty page, Atlas.ohdsi.org, the OHDSI location for all finalized cohort definitions and analysis packages, now has 113 finalized cohort packages. Prior to being adjudicated and posted, these packages were designed, characterized, evaluated and reviewed by clinical teams. It is important to note (both here and throughout all teams) that quality can not be sacrificed, even in a short time frame. Congratulations to the entire phenotype team for the hours of discussion and work that went into this effort. Patrick Ryan discusses what it takes to define a COVID-19 patient in data around the 6:15 mark of the wrap-up call.

• Huge news from the characterization group, as it has released a study package on Ed Burn’s Github repo. The team took all 12 cohort definitions to characterize hospitalization with COVID-19, as well as (among others) hospitalization with flu during the 2009-10 H1N1 pandemic. This study is being executed across multiple sites in the network. This is a huge milestone, and a show of the importance of collaboration between different teams, as the combined efforts of the phenotyping team and characterization team allowed this study to happen.

• The prediction team finalized a trio of fully-specified prediction questions with completed cohort definition packages. One such question is ‘Among patients who present with flu symptoms, who are the patients who will require admission into the hospital?’ An explanation of that study, as well as others from the prediction team, can be found around the 12:50 mark of the wrap-up call.

• Daniel Prieto-Alhambra takes over around the 22:45 mark of the wrap-up call to discuss the work of the estimation team, with a focus on the study of hydroxychloroquine, which is certainly drawing a great deal of attention right now. This study compares hydroxychloroquine to comparator drugs with a significant dataset, again highlighting the quality of real-world evidence being produced.

Though there is still more work to be done (both in the next 24 hours and beyond), we are so proud and thankful to the hard work of hundreds of collaborators around the world. We believe that this work will inform the healthcare community at a time of critical need, and we are humbled to take this journey with the rest of you!

PREVIOUS UPDATES
Day 3: Early Update
Day 2: Early Update l Late Update
Day 1: Early Update l Late Update

2 Likes
t